Primary Budd-Chiari Syndrome With Right Atrial Extension: A Rare Presentation of Intrahepatic Cholangiocarcinoma

Review began 10/06/2021
Review ended 10/17/2021
Published 10/20/2021

© Copyright 2021

Gonçalves. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Ana Gonçalves ¹

1. Internal Medicine, Hospital Fernando Fonseca, Amadora, PRT

Corresponding author: Ana Gonçalves, amlgonc@gmail.com

Abstract

Budd-Chiari syndrome (BCS) is defined as hepatic venous outflow obstruction and can be classified as primary when the obstruction is due to a predominantly venous process, caused by multiple risk factors that lead to a prothrombotic state. We report a case of a primary BCS, with an exuberant thrombus extending from the supra-hepatic vein, via the inferior vena cava, to the right atrium, a rare form of presentation of intrahepatic cholangiocarcinoma (ICC).

Categories: Internal Medicine, Oncology

Keywords: liver malignancy, cholangiocarcinoma, intrahepatic cholangiocarcinoma, right atrium thrombus, budd-chiari syndrome

Introduction

Budd-Chiari syndrome (BCS) is a rare but fatal disease caused by an obstruction in the hepatic venous outflow tract, and it can be classified as primary, when the obstruction is due to a predominantly venous process, or secondary, when the compression or invasion of the veins is caused by an extrinsic process [1]. Most patients with BCS have an underlying condition that should be promptly investigated and, if possible, treated. Multiple risk factors have been identified and are often combined in the same patient [2]. The presentation and clinical manifestations are extremely varied, so clinicians must have a high level of suspicion, and consider BCS in any patient with acute or chronic liver disease [3].

Case Presentation

We present a case of a 71-year-old male patient, admitted due to abdominal distension, pain in the right hypochondrium, and fatigue, developing over two months. He denied nausea, vomiting, anorexia, weight loss, jaundice, or other symptoms. On admission to the ED, he was conscious and oriented, with blood pressure: 120/73 mmHg, heart rate: 65 beats per minute, afebrile and eupneic with oxygen saturation: 98% in room air. Cardiopulmonary auscultation revealed rhythmic sounds, with a systolic right-sided heart murmur, and crackling rattles in both lungs. The abdomen was distended, painful on palpation, and with ascites. Blood tests revealed: aspartate aminotransferase (AST): 232 U/L, alanine aminotransferase (ALT): 121 U/L, total bilirubin: 1.06mg/dL, alkaline phosphatase 131 U/L and gamma-glutamyl transpeptidase (GGT): 182 U/L. Alpha-fetoprotein was 20 ng/mL. An abdominal Doppler ultrasound revealed moderate ascites and thrombosis of the portal vein and suprahepatic veins, along with a nodular hepatic lesion. Abdominal CT scan (Figure 1) and MRI (Figure 2) confirmed thrombosis of the portal vein, suprahepatic vein, and inferior vena cava extending to the right atrium, associated with a hepatic tumor. An ECG was performed to better characterize the intra-auricular thrombus (Figure 3). The diagnosis of intrahepatic cholangiocarcinoma (ICC) was confirmed by liver biopsy. Medical treatment was started immediately with anticoagulation and chemotherapy (gemcitabine and oxaliplatin), unfortunately, the patient had a poor therapy response, dying a few weeks later.

How to cite this article

Gonçalves A (October 20, 2021) Primary Budd-Chiari Syndrome With Right Atrial Extension: A Rare Presentation of Intrahepatic Cholangiocarcinoma. Cureus 13(10): e18935. DOI 10.7759/cureus.18935

FIGURE 1: Abdominal CT scan showing the right atrium with thrombus (red box).

FIGURE 2: Abdominal MRI (T2) showing inferior vena cava with thrombus and hepatic tumor.

Orange box: Inferior vena cava with thrombus; Green box: Hepatic tumor.

FIGURE 3: ECG (subcostal view) with right atrium thrombus (5 x 4 x 3 cm).

Arrow: Thrombus; IVC: Inferior vena cava; RA: Right atrium.

Discussion

The clinical presentation of BCS may vary from a completely asymptomatic condition to fulminant liver failure. It depends on the extent of hepatic vein occlusion and whether venous collateral circulation has developed [1,4]. Patients with fulminant courses develop acute liver failure, jaundice, and hepatic encephalopathy. Subacute form of BCS is the most common, and usually progress in months with abdominal pain, hepatomegaly, and ascites. The chronic form is manifested with complications of cirrhosis [4].

ICC is a primary tumor, originating from the bile duct lining epithelium, frequently with an indolent course. Patients often have a history of dull right upper quadrant pain and weight loss. Some patients are asymptomatic, with the lesions being detected incidentally as part of the workup of abnormal liver blood tests [5]. This case configured a subacute form of BCS, as the clinical symptoms developed progressively over two months. As for classification, we are facing a primary BCS, since the obstructive event of the hepatic veins was a venous thrombotic process, triggered by ICC.

There are several cases in the literature of ICC with secondary BCS, related to tumor invasion of the hepatic veins, however primary BCS is rarely described [6].

BCS requires prompt diagnosis and treatment. As the presentation is highly variable, clinicians should consider it if the patient presents with acute liver failure or chronic liver disease [7]. Diagnosis can be made non-invasively using Doppler USG (sensitivity and specificity of 85%) [4], which is the technique of choice for initial investigation, however, contrast-enhanced CT and MRI can better demonstrate the necrotic areas of the liver [1,7].

In this case, workup with abdominal Doppler USG showed a nodular hepatic lesion along with thrombosis of

the portal vein and suprahepatic veins. ICC usually presents as a malignant-appearing mass lesion in a non-cirrhotic liver, and the main differential diagnosis should always include a primary hepatocellular carcinoma (HCC) or metastatic adenocarcinoma [8]. Also, in ICC, the liver blood tests usually show elevated levels of alkaline phosphatase and GGT, whereas serum bilirubin levels and alpha-fetoprotein are normal [9]. Our patient presented with moderate elevation of transaminases, alkaline phosphatase, and GGT, which can be explained by both BCS and ICC. Normal levels of alpha-fetoprotein supported the diagnosis of ICC over HCC. The diagnosis was confirmed by liver biopsy.

Regarding BCS, it was possible with MRI to confirm the diagnosis and detect the extension of the thrombus from the vena cava to the right atrium, a rare form of presentation.

Treatment of BCS is based on a stepwise management strategy that includes anticoagulation, correcting underlying disorders that predispose the development of a prothrombotic state, and complications of portal hypertension [10]. Patients without progressive liver necrosis (few symptoms, relatively normal liver function tests) and with ascites, require medical therapy alone. Patients with coagulopathy, encephalopathy, or hepatorenal syndrome (signs of poor prognosis), require immediate relief of the hepatic venous outflow tract obstruction, through thrombolytic therapy or angioplasty. In extreme cases, where prior therapy has failed, liver transplantation should be considered [3,4,7].

The prognosis of patients with BCS has improved in the past decades, due to a combination of faster diagnosis, new treatment modalities, and the routine use of anticoagulation [4,11].

Conclusions

BCS has an extremely varied clinical course; therefore, clinicians must have a high level of suspicion and consider this diagnosis in any patient with acute or chronic liver disease. This case describes a rare form of presentation of an ICC through a primary BCS, with an exuberant thrombus from the suprahepatic veins to the right atrium, reminding us of the importance of always considering the presence of an underlying disorder in BCS, and consequently perform a full investigation to identify and treat the cause.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Plessier A, Valla DC: Budd-Chiari syndrome. *Semin Liver Dis.* 2008, 28:259-269. [10.1055/s-0028-1085094](https://doi.org/10.1055/s-0028-1085094)
2. Haque LY, Lim JK: Budd-Chiari syndrome: an uncommon cause of chronic liver disease that cannot be missed. *Clin Liver Dis.* 2020, 24:453-481. [10.1016/j.cld.2020.04.012](https://doi.org/10.1016/j.cld.2020.04.012)
3. Valla DC: Primary Budd-Chiari syndrome. *J Hepatol.* 2009, 50:195-203. [10.1016/j.jhep.2008.10.007](https://doi.org/10.1016/j.jhep.2008.10.007)
4. Menon KV, Shah V, Kamath PS: The Budd-Chiari syndrome. *N Engl J Med.* 2004, 350:578-585. [10.1056/NEJMra020282](https://doi.org/10.1056/NEJMra020282)
5. Brown KM, Parmar AD, Geller DA: Intrahepatic cholangiocarcinoma. *Surg Oncol Clin N Am.* 2014, 23:231-246. [10.1016/j.soc.2013.10.004](https://doi.org/10.1016/j.soc.2013.10.004)
6. Law JK, Davis J, Buckley A, Salh B: Intrahepatic cholangiocarcinoma presenting as the Budd-Chiari syndrome: a case report and literature review. *Can J Gastroenterol.* 2005, 19:723-728. [10.1155/2005/943269](https://doi.org/10.1155/2005/943269)
7. Khan F, Armstrong MJ, Mehrzad H, et al.: Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. *Aliment Pharmacol Ther.* 2019, 49:840-863. [10.1111/apt.15149](https://doi.org/10.1111/apt.15149)
8. Razumilava N, Gores GJ: Cholangiocarcinoma. *Lancet.* 2014, 383:2168-2179. [10.1016/S0140-6736\(13\)61903-0](https://doi.org/10.1016/S0140-6736(13)61903-0)
9. Nakeeb A, Pitt HA, Sohn TA, et al.: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. *Ann Surg.* 1996, 224:463-475. [10.1097/00000658-199610000-00005](https://doi.org/10.1097/00000658-199610000-00005)
10. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al.: Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology.* 2021, 73:366-413. [10.1002/hep.31646](https://doi.org/10.1002/hep.31646)
11. Valla DC: Budd-Chiari syndrome/hepatic venous outflow tract obstruction. *Hepatol Int.* 2018, 12:168-180. [10.1007/s12072-017-9810-5](https://doi.org/10.1007/s12072-017-9810-5)